CDKN2A and pancreatic neoplasm: Future studies are needed to investigate whether PR55α significantly contributes to the transcriptional suppression of p16 expression in some cancers that harbor mutant p53, such as pancreatic cancer, in which PR55α is coincidently overexpressed [27, 31, 70].